Drugs / AC699
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05654532 | Dec 2022 → Mar 2026 overdue | breast cancer | Accutar Biotechnology Inc | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-12-17 | Accutar Biotechnology Inc | Results ER degradation for ER+/HER2– advanced or metastatic breast cancer: a phase 1 trial accutarbio.com ↗
Of 26 efficacy-evaluable patients, 4 (15%) achieved partial responses and CBR was 23%. |
| 2024-08-14 | Accutar Biotechnology Inc | Regulatory Accutar Biotechnology Receives FDA Fast Track Designation for AC699 in ER+ / HER2- Breast Cancer accutarbio.com ↗ |
| 2024-06-01 | Accutar Biotechnology Inc | Results Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024 accutarbio.com ↗
Treatment with AC699 Monotherapy Resulted in 21% ORR for All Evaluable Patients, and 50% for Those Who Had an ESR1 Mutation |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-17 | Accutar Biotechnology Inc | ER degradation for ER+/HER2– advanced or metastatic breast cancer: a phase 1 trial accutarbio.com ↗ |
| 2025-12-17 | Accutar Biotechnology Inc | AC699 Phase 1 Results Published in Nature Communications accutarbio.com ↗ |
| 2024-08-14 | Accutar Biotechnology Inc | Accutar Biotechnology Receives FDA Fast Track Designation for AC699 in ER+ / HER2- Breast Cancer accutarbio.com ↗ |
| 2024-06-01 | Accutar Biotechnology Inc | Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024 accutarbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AC699 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05654532 ↗ |
| Route | Oral | “Participants will receive AC699 orally daily in 28-day cycles.” NCT05654532 ↗ |